Adaptimmune entered a strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise novel cell-based therapies in June 2014. Under the terms of the agreement, Adaptimmune will co-develop its NY-ESO-1 clinical programme and associated manufacturing optimisation work together with GSK.  GSK will have an option on the NY-ESO-1 programme through clinical proof of concept, anticipated during 2016, and, on exercise, will assume full responsibility for the programme. The companies are also co-developing other TCR target programmes and collaborating on further optimization of engineered TCR products.

Adaptimmune is now focused on its strategic partnership with GSK and developing its own internal programmes. As a leader in the field, Adaptimmune remains committed to collaborations and partnerships which enable these twin aims and the continual pursuit of excellence in the science to support its technology.

For further information, please contact: